The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer

NCT07670182 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast Cancer

Interventions

DRUG: Anti-HER2-ADC drug Deruxtepracabine

Sponsor

Tianjin Medical University Cancer Institute and Hospital